Bone Marrow Transplantation for Leukemia in Europe: Factors Influencing the Possibility of Long-Term Leukemia-Free Survival
Bone marrow transplantation (BMT) has been increasingly used for patients with acute leukemia and chronic myeloid leukemia (1,2,3). In 1979, the Leukaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EGBMT) was instituted to analyse existing data and compare results with a view to developing common protocols. The previous results have been published (4,5,6) and two detailed surveys on acute myeloblastic leukemia (ANLL) and lymphoblastic leukemia (ALL) have been reported in 1984 (7,8). Although the early results after BMT are promising, some doubts have been raised about the probability of long-term survival, viz. longer than 2 years after BMT. This survey reports the results of 34 European teams, giving data on patients with acute leukemia and chronic myeloid leukemia (CML), grafted in remission, or in chronic or accelerated phase of the disease between 1979 and December 31, 1984.
KeywordsEurope Leukemia Methotrexate Hull Mast
Unable to display preview. Download preview PDF.
- 4.Zwaan FE: Bone marrow transplantation for acute leukemia in remission–European results. Blut 41: 208–213, 1980.Google Scholar
- 5.Zwaan FE: Bone marrow transplantation for acute leukemia in remission - European results. Bone Marrow Transplantation in Europe II (eds. Touraine JL, Gluckman E, & Griscelli C), Excerpta Medica, Amsterdam, pp. 63–71, 1981.Google Scholar
- 6.Zwaan FE & Hermans J (for the EBMT Leukaemia Working Party): Allogeneic bone marrow transplantation for leukemia: European results in 264 cases. Exp Hematol 10 (suppl. 12): 96–106, 1982.Google Scholar
- 9.Hull CH & Nie NH: SPSS - update 7–9. MacGraw Hill, New York, 1981.Google Scholar
- 10.Dixon WJ, Brown MB, et al.: BMDP - statistical software 1981. University of California Press, Berkeley, CA, USA, 1981.Google Scholar